These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 30073852)

  • 1. Investigation of different types of nano drug delivery systems of atorvastatin for the treatment of hyperlipidemia.
    Mathur M; Devi Vemula K
    Drug Dev Ind Pharm; 2018 Dec; 44(12):2048-2060. PubMed ID: 30073852
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Phospholipid Complex and Submicron Emulsion Techniques for Improving Oral Bioavailability and Therapeutic Efficacy of Water-Insoluble Drug.
    Qin L; Niu Y; Wang Y; Chen X
    Mol Pharm; 2018 Mar; 15(3):1238-1247. PubMed ID: 29412674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Surface stabilized atorvastatin nanocrystals with improved bioavailability, safety and antihyperlipidemic potential.
    Sharma M; Mehta I
    Sci Rep; 2019 Nov; 9(1):16105. PubMed ID: 31695118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Co-Delivery of Atorvastatin Nanocrystals in PLGA based in situ Gel for Anti-Hyperlipidemic Efficacy.
    Kurakula M; Ahmed TA
    Curr Drug Deliv; 2016; 13(2):211-20. PubMed ID: 26549039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral nanoparticulate atorvastatin calcium is more efficient and safe in comparison to Lipicure in treating hyperlipidemia.
    Meena AK; Ratnam DV; Chandraiah G; Ankola DD; Rao PR; Kumar MN
    Lipids; 2008 Mar; 43(3):231-41. PubMed ID: 18196308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulating Drug Release and Enhancing the Oral Bioavailability of Torcetrapib with Solid Lipid Dispersion Formulations.
    Liu Y; Salituro GM; Lee KJ; Bak A; Leung DH
    AAPS PharmSciTech; 2015 Oct; 16(5):1091-100. PubMed ID: 25690735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation, characterization, and in vitro and in vivo evaluation of lovastatin solid lipid nanoparticles.
    Suresh G; Manjunath K; Venkateswarlu V; Satyanarayana V
    AAPS PharmSciTech; 2007 Mar; 8(1):24. PubMed ID: 17408223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atorvastatin calcium encapsulated eudragit nanoparticles with enhanced oral bioavailability, safety and efficacy profile.
    Kumar N; Chaurasia S; Patel RR; Khan G; Kumar V; Mishra B
    Pharm Dev Technol; 2017 Mar; 22(2):156-167. PubMed ID: 26555483
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of lipophilic emulsifiers on the oral administration of lovastatin from nanostructured lipid carriers: physicochemical characterization and pharmacokinetics.
    Chen CC; Tsai TH; Huang ZR; Fang JY
    Eur J Pharm Biopharm; 2010 Mar; 74(3):474-82. PubMed ID: 20060469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Formulation and Evaluation of Atorvastatin Calcium-Poly-ε-Caprolactone Nanoparticles Loaded Ocular Inserts for Sustained Release and Antiinflammatory Efficacy.
    Girgis GNS
    Curr Pharm Biotechnol; 2020; 21(15):1688-1698. PubMed ID: 32427080
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-PK evaluation of freeze-dried atorvastatin calcium-loaded poly-ε-caprolactone nanoparticles.
    Ahmed IS; El-Hosary R; Shalaby S; Abd-Rabo MM; Elkhateeb DG; Nour S
    Int J Pharm; 2016 May; 504(1-2):70-9. PubMed ID: 27021467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atorvastatin in nano-particulate formulation abates muscle and liver affliction when coalesced with coenzyme Q10 and/or vitamin E in hyperlipidemic rats.
    Farrag SM; Hamzawy MA; El-Yamany MF; Saad MA; Nassar NN
    Life Sci; 2018 Jun; 203():129-140. PubMed ID: 29694831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel monolithic controlled delivery system of resveratrol for enhanced hepatoprotection: nanoformulation development, pharmacokinetics and pharmacodynamics.
    Singh A; Ahmad I; Ahmad S; Iqbal Z; Ahmad FJ
    Drug Dev Ind Pharm; 2016 Sep; 42(9):1524-36. PubMed ID: 26902951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved pharmacokinetics and antihyperlipidemic efficacy of rosuvastatin-loaded nanostructured lipid carriers.
    Rizwanullah M; Amin S; Ahmad J
    J Drug Target; 2017 Jan; 25(1):58-74. PubMed ID: 27186665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preparation and characterisation of atorvastatin and curcumin-loaded chitosan nanoformulations for oral delivery in atherosclerosis.
    J B VK; Ramakrishna S; Madhusudhan B
    IET Nanobiotechnol; 2017 Feb; 11(1):96-103. PubMed ID: 28476969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chlorogenic acid stabilized nanostructured lipid carriers (NLC) of atorvastatin: formulation, design and in vivo evaluation.
    Khan S; Baboota S; Ali J; Narang RS; Narang JK
    Drug Dev Ind Pharm; 2016; 42(2):209-20. PubMed ID: 26016780
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attenuation of lipid levels in triton induced hyperlipidemia rats through rosuvastatin calcium nanoparticles: Pharmacokinetic and pharmacodynamic studies.
    Dudhipala NR; Ettireddy SR; Puchakayala GR
    Chem Phys Lipids; 2021 Jul; 237():105081. PubMed ID: 33811848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systematic approach for the formulation and optimization of atorvastatin loaded solid lipid NANOAPARTICLES using response surface methodology.
    Sarangi B; Jana U; Sahoo J; Mohanta GP; Manna PK
    Biomed Microdevices; 2018 Jun; 20(3):53. PubMed ID: 29946758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simvastatin-loaded solid lipid nanoparticles for enhanced anti-hyperlipidemic activity in hyperlipidemia animal model.
    Rizvi SZH; Shah FA; Khan N; Muhammad I; Ali KH; Ansari MM; Din FU; Qureshi OS; Kim KW; Choe YH; Kim JK; Zeb A
    Int J Pharm; 2019 Apr; 560():136-143. PubMed ID: 30753932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Design and in vivo evaluation of solid lipid nanoparticulate systems of Olanzapine for acute phase schizophrenia treatment: Investigations on antipsychotic potential and adverse effects.
    Joseph E; Reddi S; Rinwa V; Balwani G; Saha R
    Eur J Pharm Sci; 2017 Jun; 104():315-325. PubMed ID: 28408348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.